Centre Azuréen de Cancérologie
- Address
- 1 Place Du Docteur Jean Luc Broquerie, 06250 Mougins, France
Centre Azuréen de Cancérologie
The Centre Azuréen de Cancérologie is a specialized oncology research center dedicated to advancing the treatment of gynecological malignancies. The center demonstrates particular expertise in developing innovative therapeutic strategies for complex cancer cases requiring multimodal treatment approaches.
- Advanced ovarian cancer treatment optimization with targeted therapies
- Combination chemotherapy protocols with bevacizumab and PARP inhibitors
- Post-surgical maintenance therapy strategies for gynecological cancers
The center's research portfolio focuses on evaluating progression-free survival outcomes in patients with advanced ovarian, fallopian tube, and primary peritoneal cancers following complete cytoreductive surgery. Their clinical trials investigate sequential treatment regimens combining platinum-based chemotherapy with novel maintenance therapy approaches, including niraparib and bevacizumab combinations, aiming to improve long-term outcomes for patients with gynecological malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 42 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 42 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Centre Azuréen de Cancérologie
lock Showing 1 of 23 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Efficacy of Durvalumab with FOLFOX and IMRT in Localized Unresectable Esophageal Adenocarcinoma or Squamous Cell Carcinoma: A Phase II Randomized Trial | Unicancer | Phase II | Not Recruiting | May 2019 | — |
IMP list
lock Showing 1 of 42 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Carboplatin | 3 | Unknown | 2019-03-21 | 2024-07-30 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.